BioNTech’s €16.8 Billion Cash Pile Fuels $1 Billion Buyback as Cancer Data Looms

BioNTech posts Q1 net loss of €531.9M as COVID vaccine sales decline, but $1B buyback and €16.8B cash hoard underscore oncology pipeline bet. Key data readouts expected in H2 2026.

The numbers tell two stories. BioNTech posted a first-quarter net loss of €531.9 million on revenues of €118.1 million — down from €183 million a year earlier as COVID vaccine sales continue their steep decline. Yet the Mainz-based biotech is sitting on a cash hoard of €16.8 billion, and on May 7 it unveiled a $1 billion share buyback programme, a move that signals management’s conviction in a future built on oncology rather than pandemic jabs.

The buyback authorises the repurchase of up to 4.2% of outstanding American Depositary Shares through May 2027, funded entirely from existing cash reserves. CFO Ramón Zapata framed the decision as a straightforward capital allocation play: “We are confident in the long-term growth prospects of the company.” The timing is no accident. BioNTech’s stock closed the week at €79.45, down nearly 10% on the week and roughly 22% below its 52-week high of €101.90. The shares now trade well below their 200-day moving average.

Pipeline Takes Centre Stage

The quarterly loss — driven by R&D spending of $651.6 million — reflects the company’s all-in bet on oncology. The centrepiece is Pumitamig, an antibody candidate for which BioNTech launched five pivotal studies in the first quarter alone, targeting breast, gastric and lung cancers among other indications. The company expects six major data readouts from late-stage trials in the second half of 2026, including interim analyses for Gotistobart, a CTLA-4 candidate, and its FixVac platform. Management has pledged to update the market as soon as the results are available.

Cost restructuring is running in parallel. BioNTech is exploring the sale of manufacturing sites, with projected annual savings of up to €500 million by 2029 — precisely the point at which its oncology pipeline could begin generating commercial revenue.

Analyst Divergence

The market’s response to the quarterly numbers has been mixed. Canaccord cut its price target to $158 from $171, while Leerink Partners downgraded the stock to “Market Perform” with a $113 fair value estimate. Goldman Sachs maintains a buy rating and a $128 target, pointing to an addressable market opportunity exceeding $100 billion and arguing that the 2026 data could position BioNTech as a next-generation oncology player. Wells Fargo shares the bullish view. The median of nine analyst price targets over the past six months stands at $130.

BioNTech has reaffirmed its full-year 2026 revenue guidance of between €2.0 billion and €2.3 billion. With €16.8 billion in the bank and a clear strategic direction, the company is betting that its pipeline — not its pandemic past — will ultimately determine its valuation. The second-half data readouts will be the first real test of that thesis.